AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05475392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy
Description: A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR
Study NCT05475392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR
Study NCT05475392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation
Description: The exercise will be combined with the baseline treatment 3 sets PIR will be applied per session.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction, the patient is asked to relax and exhale while doing so. Following this, a gentle stretch is applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.
Study NCT06627985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GPT-4o
Description: Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
Study NCT06627985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GPT-4o mini
Description: Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o mini. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
Study NCT06627985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MedicalGPT
Description: Input all patient medical records, including text, examination reports, and imaging data, into MedicalGPT. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
Study NCT06627985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Claude-3.5 Sonnet
Description: Input all patient medical records, including text, examination reports, and imaging data, into Claude-3.5 Sonnet. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
Study NCT06627985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Claude 3 Haiku
Description: Input all patient medical records, including text, examination reports, and imaging data, into Claude 3 Haiku. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
Study NCT06627985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Real Doctors
Description: Retrospectively collect the diagnostic and treatment recommendations from the corresponding departments involved in the multidisciplinary treatment of past patients, as well as the overall recommendations.
Study NCT06307080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-mode thermal ablation device
Description: The tumor tissue was rapidly frozen until the ice ball exceeded 5mm of the lesion tissue, kept for 5 minutes, then thawed and warmed. Then, complete ablation was performed according to the radiofrequency temperature control mode of multimodal tumor therapy to ensure that the ablation area included a safe range of 5\~10mm around the tumor.
Study NCT06307080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous anti-PD-1 and chemotherapy
Description: intravenous anti-PD-1 and chemotherapy
Study NCT06307080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous anti-PD-1 and chemotherapy
Description: intravenous anti-PD-1 and chemotherapy
Study NCT04838444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA1553
Description: Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
Study NCT05086952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention A
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.
Study NCT05086952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention B
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.
Study NCT05086952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) - Intervention C
Description: Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.
Study NCT06329362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive implantation
Description: Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.
Study NCT06329362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap procedure for ridge expansion.
Description: Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.
Study NCT04860713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and ketamine
Description: Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
Study NCT04860713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurtec (Rimegepant)
Description: Drug: 75 mg of ODT
Study NCT04866420 — intervention group
Intervention type: BEHAVIORAL
Intervention: The MenFAS Study
Description: A cross over repeated exposure randomized design observational study
Study NCT05086952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (Verquvo, BAY1021189) - Intervention D
Description: Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.
Study NCT04907461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAPTAP
Description: Laparoscopic guided Transverse Abdominus Plane block
Study NCT04907461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPTAP
Description: Laparoscopic guided Transverse Abdominus Plane block
Study NCT05236153 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electroanatomic substrate mapping
Description: Participants will undergo a sinus rhythm RV substrate map using the HD Grid catheter (Abbott) and the Ensite X electroanatomic mapping system (Abbott) prior to TPVR.
Study NCT05232097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: Diaphragmatic breathing exercises
Study NCT05232097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
Study NCT04925414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygenotherapy
Description: High concentration mask delivering 15L/min of oxygen
Study NCT04925414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo air aerosol
Description: High concentration mask delivering 15L/min of air
Study NCT05942885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anxiety questionnaire
Description: Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session
Study NCT06380504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R-SWITCH integrated intervention package
Description: 1. Monthly group meetings of Alliance for Development (AFD) community groups) and their members (caregivers of children 0-59 months of age):~   * Introduction and refresher of Family-led MUAC~  * Active screening of wasting by AFD~  * Group SBCC on Infant and Young Child Feeding (IYCF), health and Water, Sanitation and Hygiene (WaSH) with a focus on SAM~  * Promotion of health services such as GMP~2. Introduction of weight-for-age Z-score \<-3 as screening criterion for passive screening by health extension workers at any contact with children (e.g. during GMP)~3. Promotion of Family-led MUAC screening and SAM awareness to fathers during male agricultural/pastoralist extension activities and by community and religious leaders (creating social support)~4. Follow-up and counselling during home visits by AFD leaders of i) earlier referred cases of SAM, ii) cases enrolled in SAM OTP, iii) and recovered SAM cases discharged from OTP~5. Strengthening communication between HEW and AFDs
Study NCT05867940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity on prescription
Description: Physical activity on prescription (PAP) is a well-established method to enhance physical activity in adults in primary care. The prescribed activity should lead to moderate increase of the pulse, such as walking, cycling, swimming, or gardening, and should be performed over a longer period of time in order to achieve a change towards a more active lifestyle. The activity may be prescribed by a physiotherapist, physician, nurse, or other health professional. PAP has shown to be feasible to increase participation in physical activity and to reduce sedentary behaviour in children with cerebral palsy.~Motivational interviewing is used for our PAP with participants with disabilities. During PAP-period, the participants are asked to fill in an activity logbook.
Study NCT06525870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 85%TCA topical application
Description: 85%TCA topical application is done at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of TCA will be applied to cover the lesion and transformation zone.
Study NCT06525870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3% acetic acid
Description: 3% acetic acid topical application is done at cervical lesion and transformation zone. Application will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of acetic acid will be applied to cover the lesion and transformation zone.
Study NCT05377034 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SIRT-Y90 with Atezolizumab + Bevacizumab
Description: Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.
Study NCT05377034 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SIRT-Y90 with Placebo (IV)
Description: Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.
Study NCT06313190 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.
Study NCT06313190 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy
Description: Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.
Study NCT06313190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients received sintilimab 200 mg every 3 weeks for up to 6 cycles, with the first dose within 1 week after the completion of SBRT.
Study NCT06560918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aids
Description: OTC devices for a week
Study NCT04803786 — intervention group
Intervention type: DRUG
Intervention: Transition from Xyrem to Xywav
Description: This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
Study NCT04985773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrosse NSE ALPHA coronary dilatation catheter
Description: The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
Study NCT05326373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous fluoride
Description: brush twice daily with stannous fluoride toothpaste for 8 weeks
Study NCT04838821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti SARS-CoV-2 equine hyperimmune serum
Description: All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
Study NCT04838821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
Study NCT05457140 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic: Genomic sequencing and molecular diagnostic results, if any.
Description: Genomic sequencing results may be used for diagnosis and treatment of participants.
Study NCT04860154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hematoporphyrin
Description: Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
Study NCT05349396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3mg Test Drug T-1 Coated Tablets
Description: Participants will receive one tablet of the test formulation T-1 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
Study NCT05349396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3mg Test Drug T-2 Coated Tablets
Description: Participants will receive one tablet of the test formulation T-2 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
Study NCT05349396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone 3mg Reference Product Coated Tablets
Description: Participants will receive one tablet of the Rerefence Product containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
Study NCT05457140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
Description: Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
Study NCT04886063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1017
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
Study NCT05958225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEE Change Business and Personal Agency Training
Description: A three day residential training based on SEE Change's Empowered Entrepreneur Training curriculum. This training will be led by a certified SEE Change trained facilitator. The workshop will include individual and group exercises that allow participants to increase their self-awareness, build mental tools for resiliency and adaptability in their life, create life visions and key tools to create behavior change. Additional exercises will include specific business related content including record keeping, financial planning and marketing strategies based on the Business Model Canvas tool.~After the 3 day training, the participants will receive a supportive message through an interactive voice recording, once a week for 6 weeks. In addition, they will be contacted once a month, for three months (either by phone or in person) by the trainer to see how they are doing on their goals.
Study NCT06196138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum
Description: In the postoperative period, starting from the 4th hour, chewing gum is done 3 times a day, morning, noon and evening, for 30 minutes each, until the patient passes the first flatus.
Study NCT06196138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Compress
Description: Starting from the 1st postoperative day, patients will receive hot application (to the lumbar region) for 10 minutes in the morning and evening. The hot application is applied by wrapping 2 towels in a water bag containing 55 ± 2 °C hot water. The water bag is applied to the lumbar region for 10 minutes with the patient in the supine position. The application is continued until the patient passes the first flatus.
Study NCT05513508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolized rotational use of interfaces
Description: The NIV mask will be changed every 6 hours, alternating two different interfaces between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask.
Study NCT05513508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
Study NCT06568796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomize controlled study
Description: eswt treatment
Study NCT06494761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zongertinib
Description: zongertinib
Study NCT06494761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam
Study NCT06494761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: omeprazole
Study NCT06494761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: repaglinide
Study NCT05899959 — intervention group
Intervention type: DEVICE
Intervention: Corsano CardioWatch 287-2
Description: Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.
Study NCT06147869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phonophoresis
Description: Phonophoresis is a method of driving topically applied substances across tissues using ultrasound (US) to enhance percutaneous absorption of selected drugs such as corticosteroids, local anaesthetics, and salicylates
Study NCT06147869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
Study NCT06276348 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing
Description: Standard diagnostic whole genome sequencing will be performed.
Study NCT04517903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye rubbing questionnaire
Description: eye rubbing questionnaire
Study NCT06276348 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BeginNGS test
Description: Genomic sequencing that screens for 434 genetic diseases.
Study NCT06276348 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WES
Description: Whole exome sequencing will be performed.
Study NCT05962138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioural Therapy for Insomnia
Description: 6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online. In addition participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.